Exicure, Inc.
XCUR Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.05
KIRA · Stoqly’s AI analyst, in plain words
- Exicure, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Exicure, Inc. lost $4.9M in fiscal 2025.
- Free cash flow was −$8.6M in fiscal 2025, — of revenue.
Market cap
$6.7M
P/E
—
Revenue
$0.0M
Net income
−$4.9M
Free cash flow
−$8.6M
Operating margin
—
Exicure, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$4.9M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Exicure, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- EXICURE, INC.
- CIK
- 0001698530
Exicure, Inc. · XCUR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.5M | $28.8M | $0.0M | $0.5M | $0.0M |
| Revenue growth | −102.9% | — | −100.0% | — | −100.0% |
| Operating margin | 12,950.1% | −6.4% | — | −2,446.4% | — |
| Net income | −$64.1M | −$2.6M | −$16.9M | −$9.7M | −$4.9M |
| Net margin | 13,271.6% | −9.0% | — | −1,940.2% | — |
| Diluted EPS | −$21.70 | −$0.56 | −$10.55 | −$4.75 | −$0.79 |
| Cash | |||||
| Cash from operations | −$34.8M | −$35.7M | −$10.4M | −$2.9M | −$8.6M |
| Capital expenditure | $1.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$35.8M | −$35.7M | −$10.4M | −$2.9M | −$8.6M |
| FCF margin | 7,409.3% | −123.7% | — | −582.0% | — |
| Share count change | −96.6% | 56.4% | −65.3% | 27.5% | 208.2% |
| Debt and strength | |||||
| Cash and short-term investments | $39.1M | $8.6M | $0.8M | $12.5M | $3.7M |
| Debt incl. finance leases | $6.9M | $0.0M | $0.0M | — | — |
| Shareholders' equity | $11.2M | $14.9M | $3.0M | $6.8M | $3.9M |
| Current ratio | 1.3x | 6.1x | 0.8x | 4.5x | 1.2x |
| Interest coverage | −37.0x | −3.1x | — | −679.6x | −4,233.0x |
| Returns and quality | |||||
| Return on capital | — | −22.8% | −534.8% | — | — |
| Return on equity | −176.3% | −19.7% | −188.4% | −197.9% | −92.5% |
| Return on tangible equity | −570.7% | −17.3% | −558.0% | −143.3% | — |
| Piotroski F-score | 3 | 4 | 2 | 4 | 1 |
| Altman Z'' | −13.8 | −20.4 | −62.0 | −43.1 | −48.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$11.6M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Exicure, Inc. · XCUR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.05 a share, the company is worth $6.7M.
Source: SEC EDGAR XBRL filings (CIK 0001698530). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.